2006
DOI: 10.2106/jbjs.e.00614
|View full text |Cite
|
Sign up to set email alerts
|

Use of Cost-Effectiveness Analysis to Evaluate New Technologies in Orthopaedics: The Case of Alternative Bearing Surfaces in Total Hip Arthroplasty

Abstract: The cost-effectiveness of alternative bearings is highly dependent on the age of the patient at the time of surgery, the cost of the implant, and the associated reduction in the probability of revision relative to that associated with conventional bearings. Our findings provide a quantitative rationale for requiring greater evidence of effectiveness in reducing the probability of implant failure when more costly alternative bearings are being considered, particularly for older patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
76
0

Year Published

2006
2006
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 60 publications
(80 citation statements)
references
References 50 publications
4
76
0
Order By: Relevance
“…However, with the increasing utilization of TJR [6], the age-related differences in the future incidence of TJR remain unexplored. This is of particular concern because more costly premium hard-on-hard bearings are intended for the younger patient population [1], which could have substantial impact on future healthcare resources. We therefore evaluated the historical changes in demand for primary and revision TJR in the younger and older patient populations.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, with the increasing utilization of TJR [6], the age-related differences in the future incidence of TJR remain unexplored. This is of particular concern because more costly premium hard-on-hard bearings are intended for the younger patient population [1], which could have substantial impact on future healthcare resources. We therefore evaluated the historical changes in demand for primary and revision TJR in the younger and older patient populations.…”
Section: Discussionmentioning
confidence: 99%
“…''Premium'' implant technologies, such as hard-on-hard bearings and hip resurfacing, have been introduced to address the increased activity and need for improved implant longevity in younger patients. However, these bearings are associated with higher costs and questions regarding their cost-effectiveness for the elderly patient population have been raised [1]. Previous projections by our group focused on estimating the total nationwide demand for primary and revision TJR [6], and not quantified the relative future size of the young TJR population in the United States that may benefit from premium implants.…”
Section: Introductionmentioning
confidence: 99%
“…Implant costs vary widely among countries and individual healthcare facilities; however, the relationship is consistent with the price of CoC being higher than the price of CoPxl, which is higher than the price of MoPxl [7]. The economic impact of these decisions on the individual patient, provider, and hospital, up to the level of payers and societies, will be important to consider moving forward.…”
Section: Discussionmentioning
confidence: 89%
“…This cohort is challenging because patients are presumed to have a higher activity level and increased life expectancy-both primary risk factors for mechanical failure of the prosthesis [37]. Therefore, use of modern materials with improved wear characteristics such as ceramics, crosslinked polyethylenes, and metal-onmetal (MoM) articulations have become popular options for younger, more active patients undergoing THA [7].…”
Section: Introductionmentioning
confidence: 99%
“…23,25 In a few studies, the cost of the device itself was deemed to be a primary cost driver. 8,10,26 However, device prices generally change over time, due to arrival of new products on the market, iterative developments, or ways in which they are procured in different health systems, and the short time horizons used in the majority of studies would not reflect price reductions over time. This differs from the case of drugs, where prices rarely change until the product loses patent protection.…”
Section: Health Outcomes and Costsmentioning
confidence: 99%